Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke

Stroke

Volumn 34, Issue 1, 2003, Pages 40-45

  Castellanos, Mar ^a   Leira, Rogelio ^c   Serena, Joaquín ^a   Pumar, José M ^c   Lizasoain, Ignacio ^b   Castillo, José ^c   Davalos, Antoni ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

Metalloproteinases; Stroke, acute; Stroke, hemorrhagic; Thrombolytic therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; GELATINASE B; HEPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BODY TEMPERATURE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; STROKE; SYSTOLIC BLOOD PRESSURE;

BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0037224938     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000046764.57344.31     Document Type: Article

References (40)

1. Toni D, Fiorelli M, Bastianello S, Sacchetti ML, Sette G, Argentino C, Montinaro E, Bozzao L. Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology. 1996;46:341-345.
2. Babikian VL, Kase CS, Pessin MS, Norrving B, Gorelick PB. Intracerebral hemorrhage in stroke patients anticoagulated with heparin. Stroke. 1989;20:1500-1503.
3. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
4. Larrue V, von Kummer R, del Zoppo G. Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997;28:957-960.
5. Levy DE, Brott TG, Haley EC Jr, Marler JR, Sheppard GL, Barsan W, Broderick JP. Factors related to intracerebral hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke. 1994;25:291-297.
6. Brott TG, Haley EC, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R, et al. Urgent therapy for stroke, 1: pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
7. Haley EC, Levy DE, Brott TG, Sheppard GL, Melvin CWW, Kongable GL, Torner JC, Marler JR. Urgent therapy for stroke, II: pilot study of tissue plasminogen activator administered within 91-180 minutes from onset. Stroke. 1992;23:641-645.
8. Hamann GF, Okada Y, del Zoppo GJ. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab. 1996;16:1373-1378.
9. Anthony DC, Ferguson B, Matyzak MK, Miler KM, Esiri MM, Perry VH. Differential matrix metalloproteinases expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol. 1997;23:406-415.
10. Clark AW, Krekoski CA, Bou S-S, Chapman KR, Edwards DR. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett. 1997;238:53-56.
11. Montaner J, Alvarez-Sabín J, Molina C, Anglés A, Abilleira S, Arenillas J, González MA, Monasterio J. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke. 2001;32:1759-1766.
12. Hoe Heo J, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab. 1999;19:624-633.
13. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab. 1996;16:360-366.
14. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. 1998;29:1020-1030.
15. Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPS are associated with blood-brain barrier opening after reperfusion in rats. Stroke. 1998;29:2189-2185.
16. Gasche Y, Fujimura M, Morita-Fujimura Y, Copin J-C, Kainrase M, Massengale J, Chan PH. Early appearance of activated metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab. 1999;19:1020-1028.
17. Romanic AM, Madri JA. Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol. 1994;4:145-156.
18. Rosenberg GA, Mun-Bryce S, Wesley M, Komfeld M. Collagenase-induced intracerebral hemorrhage in rats. Stroke. 1990;21:801-807.
19. Lapchak PA, Chapman D, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000;31:3034-3040.
20. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke. 2002;33:831-836.
21. Montaner J, Alvarez-Sabin J, Molina CA, Anglés A, Abilleira S, Arenillas J, Monasterio J. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke. 2001;32:2762-2767.
22. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
23. Hacke W, Kaste M, Fieschi C, von Kummer R, Dávalos A, Deier D, Larrue V, Bluhmki E, Davis S, Donan J, Scheneider D, Díez-Tejedor E, Trovillas P, for the Second European-Australian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
24. Robert C, Vermont J, Bosson JL. Formulas for threshold computations. Comput Biomed Res. 1991;24:514-519.
25. Hamman GF, del Zoppo GJ, von Kummer R. Hemorrhagic transformation of cerebral infarction: possible mechanisms. Thromb Haemost. 1999;82(suppl 1):92-94.
26. Hamann GI, Okada Y, Fitridge R, del Zoppo GJ. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke. 1995;26:2120-2126.
27. Rosenberg GA, Komfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res. 1992;576:203-207.
28. Tejima E, Katayama Y, Suzuki Y, Kano T, Lo EH. Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model. Stroke. 2001;32:1336-1340.
29. Davis MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, Kyriakopoulos A. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human athemsclerosis. J Pathol. 1993;171:223-229.
30. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clemens J, Davidson AH, Drummond AH, Galloway WA, Gilber L, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Woolley K. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature. 1994;370:555-557.
31. McGeehan GM, Becherer JD, Bast RC Jr, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature. 1994;470:558-561.
32. Rosenberg GA, Estrada EY, Dencoff JE, Stetler-Stevenson WG. Tumor necrosis factor-α-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res. 1995;703:151-155.
33. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab. 1998;18:1163-1172.
34. Fisher CM, Adams RD. Observations on brain embolism with special reference to the mechanism of hemorrhagic transformation. J Neuropathol Exp Neurol. 1951;10:92-94.
35. Ogada J, Yutani C, Imakita M, Ishibashi-Ueda H, Saku Y, Minematsu K, Sawada T, Yamaguchi T. Hemorrhagic infarct of the brain without a reopening of the occluded arteries in cardioembolic stroke. Stroke. 1989;20:876-883.
36. Adams HP. Emergent use of anticoagulation for treatment of patients with ischemic stroke. Stroke. 2002;33:856-861.
37. Grau AJ, Hacke W. Is there still a role for intravenous heparin in acute stroke? Yes. Arch Neurol. 1999;56:1159-1160.
38. Rantola-Ryhänen S, Ryhänen L, Nowak FV, Vitro J. Proteinases in human polymorphonuclear leukocytes: purification and characterization of an enzyme which cleaves denatured collagen and a synthetic peptide with a Gly-IIe sequence. Eur J Biochem. 1983;134:129-137.
39. Fabunmi RP, Baker AH, Murray EJ, Booth RFG, Newby AC. Divergent regulation by growth factors and cytokines of 95 Kda and 72 Kda gelatinases and tissue inhibitors of metalloproteinases 1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J. 1996;315:335-342.
40. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 2000;19:623-629.